-- 周五下午晚些时候,医疗保健类股下跌,纽约证券交易所医疗保健指数和道富医疗保健精选行业SPDR ETF (XLV) 均下跌约0.9%。iShares生物技术ETF (IBB) 下跌0.3%。 行业新闻方面,《华尔街日报》周五报道称,唐纳德·特朗普总统已批准解雇美国食品药品监督管理局局长马蒂·马卡里 (Marty Makary) 的计划。该报本周早些时候报道称,特朗普近日对马卡里批准调味电子烟和尼古丁袋耗时过长表示不满。 公司新闻方面,在周四公布第一季度业绩后,Ameriprise将Zoetis (ZTS) 的股票评级从“买入”下调至“持有”,受此影响,Zoetis股价下跌超过5%。瑞银集团也将Zoetis的目标股价从130美元下调至99美元,杰富瑞集团则从155美元下调至117美元。 Traws Pharma (TRAW) 股价飙升28%。该公司周五表示,计划利用其针对负链RNA病毒的抗病毒候选药物组合,开发治疗和预防汉坦病毒感染的潜在疗法。 据彭博社援引市场研究公司Pharmarack的数据报道,尽管仿制药大量涌入市场,诺和诺德(NVO)在印度4月份的糖尿病和减肥药物销售额仍环比增长40%,这得益于其大幅降价。诺和诺德股价上涨0.5%。 PTC Therapeutics(PTCT)股价上涨超过14%,此前该公司公布的第一季度净亏损低于预期,总收入也超过了分析师的普遍预期。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of American International Group
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $4 to $88, valuing the shares at 11x our 2026 operating EPS estimate of $8.00 (raised today by $0.15) and at 10x our 2027 EPs estimate of $8.90, vs. the one-year average forward multiple of 11x and a peer average of 13x. AIG posted strong Q1 results with operating EPS of $2.11 vs. $1.17 in the prior year, topping our $1.95 estimate and the $1.88 consensus view on improved claim trends. General Insurance net premiums written surged 24% to $5.6B, while underwriting income more than tripled to $774M with the combined ratio improving 850 bps to 87.3% on lower catastrophe losses. Though we caution Q1 results are not likely an annual run-rate, we view AIG as undervalued and believe its ability to produce above-peer underwriting profitability will provide a catalyst for shares to close their valuation gap with peers.
Coreweave Insider Sold Shares Worth $961,839, According to a Recent SEC Filing
Sachin Jain, Chief Operating Officer, on May 06, 2026, sold 7,335 shares in Coreweave (CRWV) for $961,839. Following the Form 4 filing with the SEC, Jain has control over a total of 104,068 Class A common shares of the company, with 104,068 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1769628/000176962826000225/xslF345X05/form4.xml
Coreweave Insider Sold Shares Worth $10,515,594, According to a Recent SEC Filing
Brian M Venturo, Director, Chief Strategy Officer, on May 06, 2026, sold 76,924 shares in Coreweave (CRWV) for $10,515,594. Following the Form 4 filing with the SEC, Venturo has control over a total of 411,446 Class A common shares of the company, with 223,580 shares held directly and 187,866 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1769628/000176962826000226/xslF345X05/form4.xml